Evidence map›Paper›PMID 28508029›Full record

ArticleCellular and molecular gastroenterology and hepatology2017

A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.

Mitchell E Garber, Alok Saldanha, Joel S Parker, Wendell D Jones, Katri Kaukinen, Kaija Laurila, Marja-Leena Lähdeaho, Purvesh Khatri, Chaitan Khosla, Daniel C Adelman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Current and emerging therapies for coeliac disease.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  6. Article
  7. Article
  8. Colonic Microbiota Encroachment Correlates With Dysglycemia in Humans.Cellular and molecular gastroenterology and hepatology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Mitchell E GarberAlvine Pharmaceuticals, Inc, San Carlos, California.
Alok SaldanhaInterSystems Corporation, Cambridge, Massachusetts.
Joel S ParkerLineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Wendell D JonesEA Genomics, Division of Q Solutions, Morrisville, North Carolina.
Katri KaukinenUniversity of Tampere Faculty of Medicine and Life Sciences, Tampere, Finland.
Kaija LaurilaUniversity of Tampere Faculty of Medicine and Life Sciences, Tampere, Finland.
Marja-Leena LähdeahoTampere University Hospital, Tampere, Finland.
Purvesh KhatriInstitute for Immunity, Transplantation and Infection, Stanford, California.
Chaitan KhoslaDepartment of Chemistry, Stanford, California.
Daniel C AdelmanAlvine Pharmaceuticals, Inc, San Carlos, California.
Markku MäkiUniversity of Tampere Faculty of Medicine and Life Sciences, Tampere, Finland.
Tampere University · FIStanford Medicine · USInterSystems (United States) · USQ2 Solutions (United States) · USStanford University · USTampere University · FIUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Role of Transglutaminase 2 in Celiac SprueR01DK063158 · NIDDK · STANFORD UNIVERSITY · PI CHAITAN KHOSLA · 2003 to 2026
$11.2M
NIAID NIH HHS U19 AI057229NIDDK NIH HHS R01 DK063158
6 · The paper itself

Abstract

BACKGROUND &

aimsCeliac disease (CeD) provides an opportunity to study autoimmunity and the transition in immune cells as dietary gluten induces small intestinal lesions.

methodsSeventy-three celiac disease patients on a long-term, gluten-free diet ingested a known amount of gluten daily for 6 weeks. A peripheral blood sample and intestinal biopsy specimens were taken before and 6 weeks after initiating the gluten challenge. Biopsy results were reported on a continuous numeric scale that measured the villus-height-to-crypt-depth ratio to quantify gluten-induced intestinal injury. Pooled B and T cells were isolated from whole blood, and RNA was analyzed by DNA microarray looking for changes in peripheral B- and T-cell gene expression that correlated with changes in villus height to crypt depth, as patients maintained a relatively healthy intestinal mucosa or deteriorated in the face of a gluten challenge.

resultsGluten-dependent intestinal damage from baseline to 6 weeks varied widely across all patients, ranging from no change to extensive damage. Genes differentially expressed in B cells correlated strongly with the extent of intestinal damage. A relative increase in B-cell gene expression correlated with a lack of sensitivity to gluten whereas their relative decrease correlated with gluten-induced mucosal injury. A core B-cell gene module, representing a subset of B-cell genes analyzed, accounted for the correlation with intestinal injury.

conclusionsGenes comprising the core B-cell module showed a net increase in expression from baseline to 6 weeks in patients with little to no intestinal damage, suggesting that these individuals may have mounted a B-cell immune response to maintain mucosal homeostasis and circumvent inflammation. DNA microarray data were deposited at the GEO repository (accession number: GSE87629; available: https://www.ncbi.nlm.nih.gov/geo/).

Indexed as

AutoimmunityCd, crypt depthCeD, celiac diseasecRNA, complementary RNAMucosal ImmunityOral ToleranceRegulatory B CellTG2, transglutaminase 2TR, T-cell receptorVh:Cd, ratio of villus height to crypt depthVh, villus height

Identifiers

PMID28508029
PMCPMC5413199
OpenAlexW2580774677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.